Impact of Molecular Subgroups on Prognosis and Survival Outcomes in Posterior Fossa Ependymomas: A Retrospective Study of 412 Cases

Bo Wang ¹, Minjun Yan ¹, Bo Han ¹

⁰Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing , China.

Neurosurgery +

|

March 26, 2024

View abstract on PubMed

Summary

Posterior fossa ependymomas (PFEs) subgroup A (PFA) shows worse survival than subgroup B (PFB). Aggressive treatment, including maximal resection and adjuvant therapies, is recommended for both PFA and PFB patients.

Area Of Science

Neuro-oncology
Molecular pathology
Pediatric neurosurgery

Background

Posterior fossa ependymomas (PFEs) are rare pediatric brain tumors with distinct molecular subgroups, PF-EPN-A (PFA) and PF-EPN-B (PFB).
Understanding the prognostic implications of these molecular subgroups is crucial for tailoring treatment strategies.

Purpose Of The Study

To evaluate the prognosis and survival outcomes of PFEs.
To investigate the impact of molecular subgroups (PFA vs. PFB) on patient outcomes.
To develop a predictive model for overall survival (OS) in PFEs.

Main Methods

Retrospective analysis of 412 PFE patients.
Kaplan-Meier survival analysis for OS and progression-free survival.
Cox regression for prognostic factor assessment.
Development of a nomogram for OS prediction.

Main Results

PFAs exhibited significantly poorer OS and progression-free survival compared to PFBs.
World Health Organization grade 3 was associated with worse OS.
Optimal treatment involved gross total resection followed by radiotherapy or chemoradiotherapy for PFA, and gross total resection with radiotherapy for PFB.
The developed nomogram accurately predicted OS up to 10 years.
H3K27M mutations were identified in 3.51% of PFAs.

Conclusions

PFAs have a worse prognosis than PFBs.
Both PFA and PFB necessitate maximal surgical resection and intensive adjuvant therapies for improved long-term outcomes.